Jin Medical International Ltd ZJYL

Health CareHealthcare Equipment & SuppliesChina

Last close 2.35 USD on Nov 1, 2026, −46.6% year to date

Quant rating

Quant rating D Rank 198 of 211 in Health Care

Growth D 187 of 211
Valuation D 168 of 211
Quality D 183 of 211
Revisions D 197 of 211
Momentum C 102 of 211

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 184M
Enterprise value: 173M
52-week range: 1.53 – 8.40
3-year range: 1.53 – 276.11
Dividend yield: –
Beta (5 years): 7.16
Shares outstanding: 78.4M
Next earnings: –

About the company

Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets.

Growth and profitability

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	20.7	23.5	19.8	19.2	20.8	–
Revenue growth	−12.0%	18.6%	3.3%	−7.6%	28.2%	5.0%
EPS (basic, normalized)	–	–	–	–	–	–
EPS growth	–	–	–	–	–	–
Gross margin	29.2%	40.4%	34.2%	32.3%	30.6%	33.4%
Net margin	5.8%	15.6%	14.5%	14.1%	12.7%	12.5%
ROE	4.1%	13.9%	14.7%	18.5%	21.2%	14.5%

Balance sheet, last quarter
Cash & short-term investments (mil)	–
Current ratio	–
Long-term debt (mil)	–
Net debt (mil)	–
Total equity (mil)	–
Net debt / equity	–
Net debt / EBITDA	–

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	20.7	−12.0%	8.4x	–	–	–	–	–	–

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	–	–	–	–	–	–	–	–
2027	–	–	–	–	–	–	–	–
2028	–	–	–	–	–	–	–	–

Earnings surprises

Reported results versus consensus, last 10 fiscal quarters
	FQ-9	FQ-8	FQ-7	FQ-6	FQ-5	FQ-4	FQ-3	FQ-2	FQ-1	FQ0
Sales reported (mil)	–	–	–	–	–	–	–	–	–	–
Sales mean (mil)	–	–	–	–	–	–	–	–	–	–
Surprise	–	–	–	–	–	–	–	–	–	–
EPS reported	–	–	–	–	–	–	–	–	–	–
EPS mean	–	–	–	–	–	–	–	–	–	–
Surprise	–	–	–	–	–	–	–	–	–	–

FQ0 is the most recent reported quarter, FQ-1 the one before, and so on.

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
ZJYL Jin Medical International Ltd	184M	–	5.8%	0.62x	–	–	–	–
CV CapsoVision Inc	363M	0.36x	−186.8%	25.95x	−12.2x	−15.5x	−19.4x	−24.6x
OBIO Orchestra Biomed Holdings Inc	355M	1.26x	−158.2%	12.07x	−3.9x	−3.9x	−3.2x	−3.3x
PRN Profound Medical Corp	240M	–	−264.4%	4.82x	−7.0x	−7.9x	−7.3x	−9.7x
MOBI Mobia Medical Inc	352M	–	−145.1%	12.07x	−4.2x	−5.3x	−7.5x	−7.2x
CYBQY Cyberdyne Inc	167M	−1,111.26x	4.0%	1.12x	77.2x	65.1x	21.4x	14.2x
Mean		−369.88x	−124.1%	9.44x	10.0x	6.5x	−3.2x	−6.1x
Median		0.36x	−151.6%	8.44x	−4.2x	−5.3x	−7.3x	−7.2x

Technical analysis

1M+20.5%
3M+22.4%
1Y−62.1%
3Y−75.0%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Jin Medical International Ltd, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	20.7	23.5	19.8	19.2	20.8	16.2
Cost of revenue	14.6	14.0	13.0	13.0	14.4	10.7
Gross profit	6.0	9.5	6.8	6.2	6.4	5.5
Selling, general & administrative expenses	3.9	4.4	2.4	2.2	2.2	1.9
Research & development	1.6	1.5	1.5	1.9	1.6	1.3
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	–	–	–	–	–	–
Other operating expenses	0	0	0	0	0	0
Operating income	0.6	3.6	2.9	2.1	2.6	2.4
Net interest income (expense)	0.8	0.4	0.1	0.4	0.1	−0.1
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0.2	0.1	0.2	0.2	0.2	0.1
Net income before taxes	1.6	4.2	3.2	2.7	2.9	2.4
Provision for taxes	0.2	0.8	0.3	0	0.2	0.1
Minority interest	−0.2	0.3	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	1.2	3.7	2.9	2.7	2.6	2.2
Extraordinary items	–	–	–	–	–	–
Net income	1.2	3.7	2.9	2.7	2.6	2.2
EBIT, normalized	0.6	3.6	2.9	2.1	2.6	2.4
EBITDA, normalized	0.9	3.9	3.1	2.5	3.0	2.7
Basic EPS, normalized	–	–	–	–	–	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Jin Medical International Ltd, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	29.6	26.8	16.7	7.1	5.7	2.8
Receivables	6.1	8.8	8.5	4.3	6.0	7.7
Total inventory	4.9	5.2	5.1	6.7	6.9	7.0
Prepaid expenses	3.5	2.1	0.9	0.9	0.8	0.7
Other current assets	0	0	0	0	0	0
Total current assets	44.1	42.8	31.1	18.9	19.4	18.2
Property, plant & equipment	8.0	1.7	1.5	1.6	2.1	2.3
Goodwill	–	–	–	–	–	–
Intangibles	1.1	1.1	0.2	0.2	0.2	0.2
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	0.1	0.1	0.2	0.2	0.2	0.2
Total assets	53.4	45.8	32.9	20.9	21.9	20.8
Liabilities
Accounts payable	3.3	3.0	3.4	4.1	5.4	5.4
Payable/accrued	0.7	0.4	0.3	0.4	0.7	0.2
Accrued expenses	0.1	0.2	–	–	–	–
Short-term debt	18.8	11.3	4.1	0	0	2.6
Current portion of long-term debt	–	–	–	–	–	–
Other current liabilities	1.0	2.2	1.1	1.2	1.8	1.7
Total current liabilities	23.8	17.2	8.9	5.7	7.9	10.0
Long-term debt	0	0	0	0	0	0
Minority interest	−0.1	−0.3	–	–	–	–
Other liabilities	0	0.1	0	0	0	0
Total liabilities	23.7	17.0	8.9	5.7	7.9	10.0
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0	0	0	0	0	0
Additional paid-in capital	6.7	6.7	6.4	0.1	0.1	0.1
Retained earnings (accumulated deficit)	23.8	22.6	18.9	16.1	13.4	10.7
Treasury stock	–	–	–	–	–	–
Other equity	−0.9	−0.6	−1.4	−0.9	0.6	0
Total equity	29.6	28.8	24.0	15.2	14.0	10.8
Total liabilities & shareholders' equity	53.4	45.8	32.9	20.9	21.9	20.8

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Jin Medical International Ltd, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	1.4	3.4	2.9	2.7	2.6	2.2
Depreciation, depletion & amortization	0.2	0.2	0.2	0.4	0.3	0.3
Deferred taxes	0	0	0.1	−0.1	0	−0.1
Non-cash items	0.2	0	0.1	0	−0.1	0.1
Changes in working capital	1.1	−4.9	−0.2	−1.4	3.0	0
Cash from operations	2.9	−1.2	3.1	1.6	5.8	2.5
Investing activities
Capital expenditures	−6.6	−1.1	−0.1	0	0	−0.1
Other investing cash flows	−4.2	−8.4	−7.6	−0.1	−1.0	−1.8
Cash from investing	−10.8	−9.5	−7.7	−0.1	−1.1	−2.0
Financing activities
Financing cash flow items	−0.2	4.5	−4.5	0.1	−0.1	0
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	7.6	7.2	11.4	0	−2.8	−0.4
Cash from financing	7.4	11.7	6.9	0.1	−2.9	−0.3
Foreign exchange effects	−0.1	0.3	−0.1	−0.5	0.1	−0.5
Net change in cash	−0.7	1.2	2.1	1.1	2.0	−0.3
Free cash flow	−3.7	−2.3	3.0	1.5	5.8	2.4

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.